Evidence map›Paper›PMID 32322178›Full record

ArticleReports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology

Impact of bone events on survival in solitary bone plasmacytoma.

Geovanne Pedro Mauro, Pedro Pereira Neffá, Rosangela Correa Villar, Gracia Aparecida Martinez, Heloísa de Andrade Carvalho

Open access · diamondAbstract read
In one paragraph

Article in Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 2 pooled it
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 syntheses or guidelines pooled it, 2 citations in OpenAlex.

  1. International Myeloma Working Group Recommendations for the Diagnosis and Management of Solitary Plasmacytomas.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026
    Guideline
  2. Pooled it
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Geovanne Pedro MauroDepartment of Radiology and Oncology - Radiotherapy - Faculdade de Medicina da Universidade de São Paulo. Avenida Doutor Arnaldo, 155 - Cerqueira César, 01255-000 Sao Paulo - SP, Brazil.
Pedro Pereira NeffáDepartment of Hematology, Instituto do Câncer do Estado de São Paulo (ICESP) and Medical School of Sao Paulo University, Brazil.
Rosangela Correa VillarDepartment of Radiology and Oncology, Instituto de Radiologia do Hospital das Clínicas, Medical School os Sao Paulo University, Brazil.
Gracia Aparecida MartinezDepartment of Hematology, Instituto do Câncer do Estado de São Paulo (ICESP) and Medical School of Sao Paulo University, Brazil.
Heloísa de Andrade CarvalhoDepartment of Radiology and Oncology, Instituto de Radiologia do Hospital das Clínicas, Medical School os Sao Paulo University, Brazil.
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo · BRInstituto do Câncer do Estado de São Paulo · BRCentro Infantil Boldrini · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough much studied in multiple myeloma, bone events (BE) can also cause important morbidity in bone plasmacytoma patients. To our knowledge, the effect of BE on overall survival (OS) and progression to multiple myeloma free-survival (MPFS) also has never been studied. PATIENTS AND

methodsFifty-nine patients treated from 2008 to 2017 were retrospectively assessed. All patients had histological proof of disease and were treated with radical radiotherapy (RT). Available clinical information for at least 6 months follow-up or until death had to be available. BE were described as one of the following events in the index bone: fractures, osteomyelitis, chronic pain, surgery or loss of limb function after RT.

resultsMean age at diagnosis was 57.3 years (18-80); most male (67.8%). Mean OS, bone event free-survival (BEFS), local progression-free survival (LPFS) and MPFS were 41, 36, 37 and 19 months, respectively. There were 15 deaths. BEFS (p = 0.008) and age>55y (p = 0.044) were associated with MPFS. Only BEFS correlated with OS (p = 0.029). BE was independently associated with both MPFS and OS in multivariate analysis.

conclusionBE and survival end-points were correlated. BE should be investigated in prospective trials.

Indexed as

Bone diseaseMorbidityMultiple myeloma progressionPlasmacytomaSkeletal events

Identifiers

PMID32322178
PMCPMC7171253
OpenAlexW3015362902

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.